안면용 주입제 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Facial Injectable Market Summary

The global facial injectable market size was valued at USD 11.8 billion in 2025 and is projected to reach USD 22.1 billion by 2033, growing at a CAGR of 8.2% from 2026 to 2033. A growing focus on physical appearance among consumers has driven increased demand for facial injectables in recent years.

Increasing awareness regarding minimally invasive procedures due to various beauty campaigns being organized by key players in the market is also a driving factor for market growth. According to an article published by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) in February 2025, fat grafting procedures have increased by 50%, highlighting the growing emphasis on volume restoration. In addition, with one in four surgeons anticipating increased demand for non-surgical treatments, such as injectables and skin-tightening procedures, the market is set to expand rapidly. This trend is further fueled by advancements in aesthetic medicine, evolving beauty standards, and a rising preference for minimally invasive treatments.

One of the key drivers of this market is the significant rise in global aesthetic procedures. According to the International Society of Aesthetic Plastic Surgery, nearly 38 million aesthetic procedures were performed globally in 2024, with more than 20 million being non-surgical treatments, including injectables. This reflects a 42% increase over the past four years, highlighting the strong shift toward minimally invasive solutions. The growing popularity of injectables is further supported by high procedure volumes of botulinum toxin and dermal fillers. Similarly, the data published by the American Society of Plastic Surgeons shows that over 5.3 million hyaluronic acid filler procedures were performed in 2024 alone, while botulinum toxin procedures exceeded 4.7 million annually. Additionally, globally, botulinum toxin treatments reached approximately 7.8 million procedures, making them the most commonly performed non-surgical cosmetic treatment.

Another major growth factor is the dominance of minimally invasive procedures in aesthetic practice. According to the American Academy of Facial Plastic and Reconstructive Surgery, non-invasive treatments account for nearly 80% of all cosmetic procedures in 2025, with injectables such as fillers and neurotoxins leading this segment. This clearly indicates a strong industry preference for non-surgical solutions, further boosting the demand for facial injectables.

The market is also benefiting from changing consumer demographics and rising awareness, particularly among younger populations. According to the Study published by the North American Community Hub Statistics in December 2025 indicate that 3-4% of the adult population in the U.S. underwent some form of cosmetic procedure in 2025, with the majority opting for non-surgical treatments. This shift toward early adoption and preventive aesthetics is expanding the consumer base and ensuring repeat treatment cycles, which is critical for sustained market growth.

The presence of well-established key players such as Allergan, Sinclair Pharma, and Galderma with a comprehensive portfolio of injectable fillers treating a broad range of skin indications, such as wrinkles, pigmentation, plumping of lips, scars, restoring facial fullness, as well as enhancing facial contours, is expected to drive the demand for facial injectable procedures, thereby boosting market revenue. Increasing social media exposure, rising effectiveness, and approvals for facial injectables, as well as the escalating desire among the population to look aesthetically appealing and young, are expected to drive the market during the forecast period.

Global Facial Injectable Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global facial injectable market report based on product, application, end use and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Collagen and PMMA Microspheres
• Hyaluronic Acid
  • Monophasic
  • Biphasic
• Calcium Hydroxylapatite (CaHA)
• PLLA
• PCL
• PN/PDRN
• Botulinum Toxin (Botox)
• Exosome
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Wrinkle Correction
• Lip Augmentation
• Facial Contouring
• Scar Treatment
• Volume Loss Restoration
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• MedSpas
• Aesthetic Surgery Centers
• Hospitals
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Russia
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
  • Vietnam
  • Philippines
  • Singapore
  • Malaysia
  • Taiwan
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Kuwait
  • UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Facial Injectable Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing beauty consciousness among consumers
    • 3.2.1.2. Shift in consumer preference towards minimally invasive procedures
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
• 3.3. Facial Injectable Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Facial Injectable Market: Product Estimates & Trend Analysis

• 4.1. Global Facial Injectable Market: Product Dashboard
• 4.2. Global Facial Injectable Market: Product Movement Analysis
• 4.3. Global Facial Injectable Market by Product, Revenue
• 4.4. Collagen and PMMA Microspheres
  • 4.4.1. Collagen and PMMA Microspheres market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Hyaluronic Acid
  • 4.5.1. Hyaluronic Acid market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.2. Monophasic
    • 4.5.2.1. Monophasic market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.3. Biphasic
    • 4.5.3.1. Biphasic market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Calcium Hydroxylapatite (CaHA)
  • 4.6.1. Calcium Hydroxylapatite (CaHA) market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. PLLA
  • 4.7.1. PLLA market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. PCL
  • 4.8.1. PCL market estimates and forecasts 2021 to 2033 (USD Million)
• 4.9. PN/PDRN
  • 4.9.1. PN/PDRN market estimates and forecasts 2021 to 2033 (USD Million)
• 4.10. Botulinum Toxin (Botox)
  • 4.10.1. Botulinum Toxin (Botox) market estimates and forecasts 2021 to 2033 (USD Million)
• 4.11. Exosome
  • 4.11.1. Exosome market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Facial Injectable Market: Application Estimates & Trend Analysis

• 5.1. Global Facial Injectable Market: Application Dashboard
• 5.2. Global Facial Injectable Market: Application Movement Analysis
• 5.3. Global Facial Injectable Market Estimates and Forecasts, By Application, Revenue (USD Million)
• 5.4. Wrinkle Correction
  • 5.4.1. Wrinkle Correction market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Lip Augmentation
  • 5.5.1. Lip Augmentation market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Facial Contouring
  • 5.6.1. Facial Contouring market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Scar Treatment
  • 5.7.1. Scar Treatment market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Volume Loss Restoration
  • 5.8.1. Volume Loss Restoration market estimates and forecasts 2021 to 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Facial Injectable Market: End Use Estimates & Trend Analysis

• 6.1. Global Facial Injectable Market: End use Dashboard
• 6.2. Global Facial Injectable Market: End use Movement Analysis
• 6.3. Global Facial Injectable Market Estimates and Forecasts, by End use, Revenue (USD Million)
• 6.4. MedSpa
  • 6.4.1. MedSpa market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Aesthetic Surgery Centers
  • 6.5.1. Aesthetic Surgery Centers market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Hospitals
  • 6.6.1. Hospitals market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Facial Injectable Market: Regional Estimates & Trend Analysis by Product, Application, and End use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.9. Russia
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Regulatory framework/ reimbursement structure
    • 7.4.9.3. Competitive scenario
    • 7.4.9.4. Russia market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Singapore
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework/ reimbursement structure
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Singapore market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Malaysia
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Regulatory framework/ reimbursement structure
    • 7.5.8.3. Competitive scenario
    • 7.5.8.4. Malaysia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.9. Taiwan
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Regulatory framework/ reimbursement structure
    • 7.5.9.3. Competitive scenario
    • 7.5.9.4. Taiwan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.10. Vietnam
    • 7.5.10.1. Key country dynamics
    • 7.5.10.2. Regulatory framework/ reimbursement structure
    • 7.5.10.3. Competitive scenario
    • 7.5.10.4. Vietnam market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.11. Philippines
    • 7.5.11.1. Key country dynamics
    • 7.5.11.2. Regulatory framework/ reimbursement structure
    • 7.5.11.3. Competitive scenario
    • 7.5.11.4. Philippines market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
  • 8.1.1. Key company market share analysis, 2025
  • 8.1.2. Ipsen
    • 8.1.2.1. Company overview
    • 8.1.2.2. Financial performance
    • 8.1.2.3. Product benchmarking
    • 8.1.2.4. Strategic initiatives
  • 8.1.3. Abbvie
    • 8.1.3.1. Company overview
    • 8.1.3.2. Financial performance
    • 8.1.3.3. Product benchmarking
    • 8.1.3.4. Strategic initiatives
  • 8.1.4. Medytox Inc.
    • 8.1.4.1. Company overview
    • 8.1.4.2. Financial performance
    • 8.1.4.3. Product benchmarking
    • 8.1.4.4. Strategic initiatives
  • 8.1.5. Merz GmbH and Co. KGaA
    • 8.1.5.1. Company overview
    • 8.1.5.2. Financial performance
    • 8.1.5.3. Product benchmarking
    • 8.1.5.4. Strategic initiatives
  • 8.1.6. Revance Therapeutics, Inc.
    • 8.1.6.1. Company overview
    • 8.1.6.2. Financial performance
    • 8.1.6.3. Product benchmarking
    • 8.1.6.4. Strategic initiatives
  • 8.1.7. Galderma
    • 8.1.7.1. Company overview
    • 8.1.7.2. Financial performance
    • 8.1.7.3. Product benchmarking
    • 8.1.7.4. Strategic initiatives
  • 8.1.8. Sinclair Pharma
    • 8.1.8.1. Company overview
    • 8.1.8.2. Financial performance
    • 8.1.8.3. Product benchmarking
    • 8.1.8.4. Strategic initiatives